Abstract 852P
Background
Overexpression of transcription factor c-MAF is found in about 50% of multiple myeloma cases, and associated with the prognostically unfavorable t(14;16) translocation subtype. Genetic alterations can modify the epigenome through metabolite availability that act as substrates in histone modifications, but how this translates into specificities in gene regulation is unclear.
Methods
We integrated a multi-omics approach using metabolome profiling to characterize the metabolic phenotype and RNA-sequencing to identify key metabolic genes as a means to uncover novel associations involved in the distinct reprogramming of t(14;16) metabolism.
Results
Here, we report a novel involvement of c-MAF in metabolically-driven histone acetylation, including the superenhancer mark H3K27ac, through altering acetyl-CoA metabolism. To sustain high levels of acetylation, c-MAF acquired the metabolic flexibility to utilize glutamine in addition to glucose, feeding into the tricarboxylic acid (TCA) cycle as acetyl-CoA sources. Loss-of-function studies indicated that c-MAF is important for citrate-derived acetyl-CoA and H3K27ac levels through metabolic enzymes citrate synthase (CS) and ATP-citrate lyase (ACLY). Furthermore, blocking citrate export from mitochondrial via CRISPR/Cas9 targeting of SLC25A1 reproduced the reductions in H3K27ac. Silencing of c-MAF also displayed defective mitochondrial oxidative phosphorylation attributed to reduced metabolic flux through TCA cycle and downregulation of electron transport chain complex I/II expression, without affecting mitochondrial DNA content. To identify c-MAF-regulated superenhancer genes, we overlapped our previously published H3K27ac ChIP-seq dataset on t(14;16) MM cell lines with c-MAF RNA-seq data. We found signal enrichment of H3K27ac at ZC3H3 locus responsible for its transcriptional upregulation, and knockdown of ZC3H3 inhibited cell growth specifically in the t(14;16) subtype.
Conclusions
Altogether, we demonstrated a non-canonical c-MAF role in epigenetics that is connected to its altered metabolic state, and suggest metabolic disruptions as a new therapeutic direction in t(14;16) myeloma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Medical Research Council (NMRC).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
990P - Prognosis prediction for unresectable hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy using convolutional neural network model
Presenter: bing quan
Session: Poster session 18
991P - Real-world comparison of trans-arterial chemoembolization and bland embolization for the treatment of hepatocellular carcinoma: A propensity score analysis
Presenter: Allan Ramos-Esquivel
Session: Poster session 18
993P - Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma (IMbrave150 and Korean patients cohorts)
Presenter: Hongjae Chon
Session: Poster session 18
995P - Real-world treatment patterns, survival and costs in advanced hepatocellular carcinoma (aHCC) in Ontario, Canada
Presenter: Dominick Bossé
Session: Poster session 18
996P - Transarterial chemoembolization combined donafenib with/without programmed death-1 inhibitors for initially unresectable hepatocellular carcinoma in a multicenter retrospective study
Presenter: Xuhua Duan
Session: Poster session 18
998P - Efficacy and safety of curative hepatectomy after conversion therapies for initial unresectable hepatocellular carcinoma: A multicenter propensity score matching study
Presenter: Rong-yun Mai
Session: Poster session 18